|
|
||||||||
DNAX Research, Palo Alto, CA 94304
| Abstract |
|---|
|
|
|---|
4
7. Homing and chemokine receptor
coexpression studies detailed in this study suggest that the
CLA+/CCR10+ memory CD4 T cell population
contains members that have access to both secondary lymphoid organ and
skin compartments; and therefore, can act as both "central" and
"effector" memory T cells. Consistent with this effector phenotype,
CLA+/CCR10+ memory CD4 T cells from normal
donors secrete TNF and IFN-
but minimal IL-4 and IL-10 following in
vitro stimulation. Interactions of CCR10 and its skin-associated ligand
CC ligand 27 may play an important role in facilitating memory T
cell entry into cutaneous sites during times of
inflammation. | Introduction |
|---|
|
|
|---|
) that direct how the
immune system will combat the pathogen. Equally important is the
reprogramming of surface homing receptors that enable memory T cells to
enter into peripheral tissues where the foreign invader may be
found. A four-step model of leukocyte egress from the blood into lymphoid and extralymphoid organs has been proposed: step 1) blood-borne leukocytes roll along the vascular endothelium; step 2) a pertussis toxin-sensitive activation event occurs within the leukocyte; step 3) activation-dependent, integrin-dependent leukocyte adhesion to the vascular endothelium; and step 4) leukocyte diapedisis into the surrounding tissue that is mediated by a gradient of tissue-expressed chemoattractant (1, 2). Importantly, the molecules that participate in each of these steps during memory T cell homing into many organs are different and different types of memory T cells exhibit distinct homing patterns.
Skin-homing cutaneous lymphocyte-associated Ag
(CLA+)3
memory T cells preferentially home to
cutaneous sites and are found at high frequency in inflammatory
cutaneous lesions. The CLA Ag is a posttranslational glycosylation of
P-selectin glycoprotein ligand 1 (3) (and
possibly other proteins) that allows skin-homing memory T cells to roll
on superficial dermal endothelium-expressed E-selectin (CD62E) during
times of cutaneous inflammation (4, 5, 6, 7, 8) and may fulfill the
step 1 role in the multistep model of leukocyte extravasation.
CLA+ memory T cells express the integrins
CD11a/CD18 (
L
2,
LFA-1) and CD49d/CD29
(
4
1) that bind
inflamed endothelium-expressed ICAM-1 and VCAM-1 and can mediate step 3
adhesion (8). Among leukocytes, the message for the
G-protein-coupled receptor CCR10 is exclusively expressed by
CLA+ skin-homing memory T cells and the CCR10
ligand CC ligand (CCL)27 (CTACK/ALP/ILC/ESkine) is exclusively
made by skin-associated keratinocytes (9, 10, 11). It has been
proposed that CCL27 interacting with CCR10 on skin-homing memory T
cells could play a role in either or both step 2 (activation) or step 4
(diapedisis) to facilitate CCR10+ T cell entry
into inflamed cutaneous sites.
To fully address the potential role that CCR10 plays in memory T cell entry into cutaneous (and other) sites and to address the likely outcome of CCR10+ T cell entry into inflamed cutaneous lesions, a CCR10 Ab was developed to identify the panel of homing receptors that CCR10+ T cells coexpress and to address the cytokine secretion profiles of these cells following activation. The results of this study will have broad implications into the mechanisms of T cell entry into skin during times of cutaneous infection and in T cell-mediated skin diseases such as contact hypersensitivity, psoriasis, and atopic dermatitis (AD).
| Materials and Methods |
|---|
|
|
|---|
Mice were immunized with Ba/F3 cells transfected with a human
CCR10 construct. After a final boost, the spleen was harvested and
fused with SP/0 cells by conventional methods. Supernatants from wells
containing viable cells were tested on rat Y3 myeloma cells transfected
with CCR10. Confirmation of positive clones was performed by testing
supernatants against CCR10 transfectants in human TF-1 and mouse Ba/F3
cells, a CCL27-responsive human T cell line (S. Hudak and L.
McEvoy, manuscript in preparation), and the
CCL27-responsive CLA+ memory CD4 T cell
population from peripheral blood. Hybridomas were subcloned by limiting
dilutions two additional times, Ab purified (in-house and at Sierra
Biosciences, Gilroy, CA) and biotinylated (EZ-Link
Sulfo-NHS-LC-LC-Biotin; Pierce Rockford, IL). The selected clones 37,
1363, and 1908 were mouse IgG1, IgG2a, and IgG1 Abs, respectively (all
have
L chains). Unconjugated Abs were visualized with PE-conjugated
goat anti-mouse IgG secondary reagents (Jackson ImmunoResearch
Laboratories, West Grove, PA).
Human peripheral blood cell isolation
Human PBMCs were obtained from healthy donors by conventional Ficoll/Histopaque-1077 (Sigma-Aldrich, St. Louis, MO) sedimentation of buffy coats obtained from the Stanford University Blood Bank (Stanford, CA). All donors were anonymous which precluded assessment of how CCR10 expression may differ based on age, sex, or race. Donors were negative for a panel of infectious agents (syphilis, hepatitis B and C, human T cell leukemia virus, and HIV). T cells were isolated using a Pan T cell isolation kit (Miltenyi Biotec, Auburn, CA) or T cell enrichment columns (R&D Systems, Minneapolis, MN) according to the manufacturers protocols. Granulocytes were obtained by collecting venous blood and preparing according to Ref. 12 . Platelets were obtained by collecting venous blood in yellow top ACDA tubes, low-speed centrifugation, and harvesting the top platelet-rich plasma layer (13).
Flow cytometry
Cells were stained on ice in HBSS (BioWhittaker, Walkersville, MD) containing 12% FBS (HyClone Laboratories, Logan, UT), 10 mM HEPES, and 0.1% sodium azide or PBS containing 1% FBS and 0.1% sodium azide. Analysis was performed on a FACSCalibur (BD Immunocytometry Systems, San Jose, CA). The biotinylated anti-CCR10 Ab was detected using PE- or allophycocyanin-conjugated streptavidin (BD PharMingen, San Diego, CA).
Lineage and naive/memory Ags were visualized using CyChrome- and allophycocyanin-conjugated mouse anti-hCD4 (clone RPA-T4; BD PharMingen), FITC- and PE-conjugated mouse anti-hCD8 (clone HIT8a; BD PharMingen), PE-conjugated mouse anti-hCD14 (clone M5E2; BD PharMingen), FITC-conjugated mouse anti-hCD16 (clone 3G8; BD PharMingen), FITC-conjugated mouse anti-hCD19 (clone HIB19; BD PharMingen), FITC-conjugated mouse anti-hCD41a (clone HIP8; BD PharMingen), CyChrome-conjugated mouse anti-hCD45RA (clone HI100; BD PharMingen), and PE- and CyChrome-conjugated mouse anti-hCD45RO (clone UCHL1; BD PharMingen).
Homing receptor expression was evaluated using PE-conjugated
mouse anti-hCD11a (clone HI111; BD PharMingen), PE-conjugated mouse
anti-hCD18 (clone L130; BD PharMingen), PE-conjugated mouse
anti-hCD62L (clone DREG 56; BD PharMingen), PE-conjugated rat
anti-human Integrin
7 (clone FIB504; BD
PharMingen), and FITC-conjugated rat anti-hCLA (clone HECA452; BD
PharMingen).
Chemokine receptor (CKR) expression was evaluated using PE-conjugated mouse anti-hCCR6 (clone 11A9; BD PharMingen) and PE-conjugated mouse anti-CXCR3 (clone1C6; BD PharMingen), and PE-conjugated anti-hCXCR4 (R&D Systems). CCR7 was detected using an unconjugated mouse anti-hCCR7 mAb (clone 2H4; BD PharMingen) followed by PE-conjugated goat anti-mouse IgM (Jackson ImmunoResearch Laboratories). CCR4 was detected with an unconjugated mouse anti-hCCR4 mAb (clone 1G1; BD PharMingen) followed with PE-conjugated goat anti-mouse IgG (Jackson ImmunoResearch Laboratories).
Migration assays
Migration assays were conducted as described in Ref. 14 with the following modifications. T cell populations were isolated as described above and incubated in Yssels medium containing penicillin-streptomycin and 10 mM HEPES for >1 h. Chemokines were diluted in above medium. Following chemotaxis assay using 5-micron Transwell inserts, responding cells and added counting beads were stained as described in the figure legends and fixed in PBS/2% paraformaldehyde before analysis by flow cytometry. Calculation of percentage of migration was as described in Ref. 15 .
ELISPOT analysis of sorted populations
Cells were stained with a mixture of labeled Abs described above
and sorted. Sorted cells were pelleted and resuspended in 700 µl of
Yssels medium/penicillin-streptamycin/25 mM HEPES containing 50 U/ml
of human IL-2 and an aliquot counted to determine cell concentration.
Ninety-six-well MultiScreen-IP plates (Millipore, Bedford, MA) were
precoated overnight with Abs against human IL-4, IL-10, IFN-
, or TNF
according to manufacturers protocol (Diaclone, Cedex, France).
For wells with anti-CD3 stimulation, 1 µg/ml anti-hCD3 was
included with each anti-cytokine Ab. Plates were washed and blocked
with PBS/2% skimmed dry milk. Plates were washed and wells filled with
150 µl of medium above (Basal), or medium containing 1 µg/ml
anti-hCD28 (CD3/CD28) or 10 ng/ml PMA and 500 ng/ml ionomycin
(Ion). A total of 50 µl of sorted cells were placed in the top well
of each column and mixed with 150 µl of medium. A total of 50 µl of
diluted cells was transferred to the next well in the column using a
multichannel pipette and mixed. This was repeated down the column to
dilute the number of cells plated by 4-fold in each row. Plates were
placed in a nonvibrating incubator overnight and developed according to
manufacturers protocol. Briefly, plates were washed, plate-bound
cytokine was detected with a biotinylated anti-cytokine Ab, plate
washed, biotinylated Ab detected with HRP-conjugated streptavidin, and
spots visualized with nitroblue
tetrazolium/5-bromo-4-chloro-3-indolylphosphate p-toluidine
salt after extensive washing. Number of spots was quantified
using a dissecting microscope and the frequency of cytokine-secreting
cells (CSCs) in a population presented as the percentage of plated
cells that gave a detectable "spot" for each cytokine.
Quantification of cytokine production
Enriched T cell preparations were stained with Abs described in
the figure legend and sorted. Sorted cells were pelleted and
resuspended in Yssels medium/penicillin-streptamycin/25 mM HEPES
containing 50 U/ml human IL-2 and an aliquot counted to determine cell
concentration. Wells of a 96-well tissue culture plate were filled with
150 µl of medium above (Basal) or 10 ng/ml PMA and 500 ng/ml Ion. A
total of 50 µl of sorted cells were placed into a well of each
stimulation condition. Plates were incubated for 20 h, and
supernatants harvested, centrifuged; and cleared supernatant frozen
till analyzed. The concentration of cytokines in the supernatants was
quantified by a Cytometric Bead Array kit (BD Biosciences, Mountain
View, CA) and concentrations normalized to nanograms per milliliter
cytokine produced by 2E4 cells activated in 200 µL of medium
for
20 h.
| Results |
|---|
|
|
|---|
|
|
|
4
7 is expressed at
low levels on naive T cells, but a subset of memory T cells express
high levels and preferentially home to gut peripheral tissues (i.e.,
the lamina propria and the intraepithelial lymphocyte compartment). In
contrast, CLA is not expressed by naive T cells, but is expressed on a
memory T cell subset that preferentially homes to the peripheral skin
compartment. A third memory population is the
4
7-/CLA-
memory T cell population that contains cells that may home to other
extralymphoid sites (1).
Fig. 3
B shows that practically no
CCR10+ memory CD4 T cells express detectable
levels of
7 integrin (Fig. 3
B,
left panel). In contrast, most CCR10+
cells are found within the CLA+ memory CD4 T cell
subset (Fig. 3
B, middle panel). The
CLA+/CCR10+ subset is
9 ± 2% (mean ± SD, n = 5 donors) of the
memory CD4 T cell population, and 28% of CLA+
memory CD4 T cells express CCR10. All donors tested have a minor
population of CCR10+ memory CD4 T cells that
express undetectable levels of CLA (Fig. 3
B, middle
panel, upper left quadrant). The percentage
of these cells in the memory CD4 T cell population is 1.2 ± 0.7%
(mean ± SD, n = 5 donors). Importantly,
CLA+/CCR10+ memory CD4 T
cells (Fig. 3
B, right panel, dark line) have
higher levels of CLA than the
CLA+/CCR10- memory CD4 T
cell population (Fig. 3
B, right panel, light
line). Additionally,
CLA+/CCR10+CD4 T cells
express high levels of the integrin CD11a/CD18 (LFA-1,
L
2) and have a range
of CD62L expression from high to undetectable (data not shown).
The bulk of the
CCR10+CD8high T cells are
also found in the CLA+ (Fig. 3
D,
right panel) and
7- (Fig. 3
D,
left panel) subpopulation. The
CLA+/CCR10+ subset is
0.6 ± 0.5% (mean ± SD, n = 8 donors) of
the CD8high T cell population, and
10% of
CLA+ CD8high T cells
express CCR10. There is little evidence for a
CLA-/CCR10+CD8high
T cell population in the normal donors tested. Further characterization
of the CCR10+CD8high T cell
population is hampered by its very low frequency in blood and
problematic background staining with isotype control Ab; therefore,
this aspect of CCR10 biology will not be further characterized in this
report.
Chemokines interacting with pertussis toxin-sensitive CKRs are
postulated to facilitate leukocyte entry into tissues by acting as
either or both step 2 activation ligands or step 4 chemoattractants. In
addition to CCR10, there are 18 G-protein-coupled receptors that have
chemokine ligands. We have analyzed a subset of CKRs that are important
in memory T cell biology, and addressed which of these CKRs are
coexpressed on CCR10+ memory CD4 T cells. The
ligands for CCR4 (16, 17, 18), CCR6 (19, 20), and
CXCR3 (18, 21) are found in inflamed skin, and ligands for
CCR7 are found in both lymphoid and peripheral tissues
(1). Coexpression of different CKRs investigates the
potential for cooperative or redundant mechanisms to facilitate T cell
entry into peripheral tissues during immune surveillance or during T
cell-mediated disease episodes. The different respective isotype Ab
staining controls on CLA+ memory CD4 T cells are
shown in the second row (Fig. 4
, FJ).
|
|
) but not
CLA+/CCR10- (
) memory
CD4 T cells migrate to the CCR10 ligand CCL27 confirming that
anti-CCR10 Ab staining identifies the CCL27-responsive cells within
the CLA+ memory CD4 T cell population. The
CLA+/CCR10+ memory CD4 T
cell population also had a more prominent response to the CCR4 ligand
CCL17/thymus and activation-regulated chemokine than
CLA+/CCR10- memory CD4 T
cells confirming the positive association between CCR10 and CCR4
expression (Fig. 5
, Fig. 5
-inducible protein
(IP)-10 (Fig. 5
(data not shown). In sharp contrast to the flow
cytometric analysis,
CLA-/CCR10+ memory CD4 T
cells (
) did not respond significantly to CCL27. They also did not
respond appreciably to CCL17/TARC, CCL20/MIP-3
, and CXCL10/IP-10.
However, these cells were fully capable of migration based on their
high chemotactic response to the CCR7 ligand CCL21/SLC and CXCR4 ligand
CXCL12/stromal cell-derived factor-1
(data not shown). The
specificity and selectivity of the migratory response by the two
CLA+ populations to skin-associated chemokines
were demonstrated by their nonresponsiveness to the B cell
follicle-associated chemokine CXCL13/B cell-attracting
chemokine-1 (data not shown).
|
The homing receptors and CKRs expressed by CCR10+
memory T cells suggested that they would access both inflamed cutaneous
sites (CLA, CD11a/CD18, CCR4/6/10, CXCR3) and secondary lymphoid organs
(CD62L, CD11a/CD18, CCR7) to search for foreign Ags and establish an
appropriate immune response to combat the pathogen. A primary mechanism
to establish the type of immune reaction is by Ag-stimulated secretion
of proinflammatory cytokines (e.g., TNF) in concert with Th1 (e.g.,
IFN-
), Th2 (e.g., IL-4), and/or other (e.g., IL-10) cytokines. The
cytokine secretion profiles of
CLA+/CCR10+ memory CD4 T
cells was compared with
CLA+/CCR10- and
CLA-/CCR10+ memory CD4 T
cells by direct measurement of the frequency of CSCs within each
population and by the bulk cytokine secretion capacity of each
population following anti-CD3/CD28 or PMA/Ion stimulation.
The sorting regions used to isolate the three populations are shown in
Fig. 6
A. No or very few cells
secreting IFN-
, IL-4, IL-10, or TNF were detected in any population
in the absence of in vitro stimulation (Fig. 6
C, open
bars), demonstrating that these sorted memory CD4 T cells are not
in vivo activated in the blood from the nondiseased healthy donors
tested. PMA/Ion activation (Fig. 6
C, right panel,
hatched bars) gave the maximal number of detectable CSCs in each sorted
population compared with anti-CD3/CD28 stimulation (Fig. 6
C, left panel, filled bars), but the cytokine
secretion profile differences among the three populations was similar
regardless of the type of stimulation. IL-4 and IL-10 CSCs were either
undetectable or marginally observable in
CLA-/CCR10+ (R1),
CLA+/CCR10+ (R2), and
CLA+/CCR10- (R3) memory
CD4 T cell populations regardless of the activation protocol. In
contrast, a great percentage of cells in all three populations secreted
detectable levels of TNF following PMA/Ion stimulation (Fig. 6
C, right panel, hatched bars), and TNF-CSCs were
the most numerous CSCs following anti-CD3/CD28 stimulation (Fig. 6
C, left panel, filled bars). The IFN-
CSCs
frequency was intermediate between TNF and IL-4/10 CSC frequencies for
both activation protocols.
|
were the most abundant cytokines
secreted by all three populations. All three sorted populations also
expressed very low levels of IL-4 (
0.2 ng/ml) and IL-10 (
0.1
ng/ml) following PMA/Ion stimulation; levels that are barely detectable
on the scale shown in Fig. 6| Discussion |
|---|
|
|
|---|
CLA+ memory T cells home to inflamed cutaneous
lesions (5, 6, 24, 25, 26, 27, 28, 29, 30, 31, 32) by binding E-selectin expressed by
superficial dermal postcapillary venules (4, 5, 6, 7, 8, 33). They
can constitute the major hematopoietic cell type in a skin lesion and
in afferent lymph draining the skin (34), even though
these cells are a minor population in blood (8, 24, 25).
Immunological memory to cutaneous Ags (e.g., nickel, house dust mite)
is mainly carried within this population compared with memory for
systemic Ags (e.g., tetanus toxid) that is found in the much larger
CLA- memory T cell population (5, 32, 35, 36, 37). CLA+ T cells make Th1 (IFN-
),
Th2 (IL-4, IL-5), and other (IL-10) cytokines that may direct how the
immune system will mount a response (25, 27, 32, 35, 37, 38, 39, 40). Based on these attributes, CLA+ T
cells are thought to contribute significantly to the host response to
cutaneous encountered Ags.
E-selectin is absent or expressed at very low levels under normal conditions, but is up-regulated on endothelial cells in response to inflammation (41, 42, 43). Leukocyte-expressed CLA binding endothelium-expressed E-selectin facilitates leukocyte slow rolling on the endothelium. Importantly, E-selectin is up-regulated in other inflamed organs, not just skin (42, 44), but CLA+ T cells are mostly found in inflamed cutaneous sites (24, 45, 46, 47, 48, 49). What can explain the dichotomy between E-selectin expression in many sites, yet CLA+ T cells only being found in cutaneous lesions? Leukocyte integrins binding endothelium-expressed ICAM-1 and VCAM-1 can mediate step 3 activation-dependent adhesion (8), but these integrin ligands are present in many organs and would not provide a skin selectivity step (1). Therefore, it was postulated that a skin-specific activation cue (step 2) or chemoattractant (step 4) might confer skin-specific homing to the CLA+ T cell population or to a subset of cells within this population. CCL27 is the only skin-specific chemokine known (9) and by interacting with CLA+/CCR10+ memory T cells, it may provide the postulated skin-specific step that facilitates these cells entry into cutaneous sites.
CCR10 is not found on any peripheral blood leukocyte population with the exception of a small subset of memory CD4 and CD8high T cells that predominately express high levels of CLA in the donors tested in this study. The restricted CCR10 expression to these cells correlated with the restricted migratory response by only these cells to the CCR10 ligand CCL27, suggesting that CCL27 does not have another receptor (9). However, other leukocytes may express CCR10 at developmental stages that are not found in peripheral blood, or at developmental stages in blood that are below our level of detection. Importantly, CCR10 is expressed by other nonleukocyte populations in skin, as assessed by both message (10) and by Ab staining (50).
CCR10 coexpression with some but not other CKRs on a population level suggests a wide array of combinatorial interactions with different sets of chemokines that may target the CCR10+ memory CD4 T cell population into a variety of microenvironmental niches. Additionally, this complexity may provide redundant mechanisms to allow cell entry and dispersion within a tissue. CLA+/CCR10+ memory CD4 T cells tended to have undetectable or low levels of CXCR3 in comparison to the CLA+/CCR10- memory CD4 T cell population. However, the functional chemotactic responses by both populations to CXCR3 ligands suggest the lower CXCR3 levels are sufficient to mediate step 4 diapedisis. The in vivo significance of lower CXCR3 expression by CLA+/CCR10+ vs CLA+/CCR10- T cells is unclear at present, but it will be interesting to determine whether this observation is applicable to Th1-associated skin diseases where CLA+/CXCR3+ memory T cells are prevalent, such as psoriasis (18).
Practically all CCR10+ memory CD4 T cells
coexpressed CCR4, regardless of CLA expression. Both CCR4 and CCR10
ligands stimulated chemotaxis and triggered rapid integrin-dependent
adhesion of CLA+ memory CD4 T cells to ICAM-1
(Ref. 16 and S. Hudak, unpublished observations). However,
CCR4 is expressed on most (>75%) CLA+ memory
CD4 T cells, and is also expressed on a significant subset of
CLA- memory CD4 T cells (Fig. 4
and Refs.
16 and 40) unlike CCR10, which is on a
smaller subset of CLA+ memory CD4 T cells (28%)
and very few (1.2%) CLA- memory CD4 T
cells.
The ligands for CCR4 and CCR10 are found in cutaneous sites, suggesting their involvement in T cell entry and dispersion within the skin. CCL27 message is constitutively expressed and is unchanged in various skin diseases (10), although CCL27 protein is increased in psoriasis, AD, and allergic contact dermatitis by immunohistochemistry (50). In vitro results indicate that CCL27 is expressed by keratinocytes and not by human dermal microvascular endothelial cells where the initial steps in skin homing occur (10), although CCL27 protein is associated with the inflamed endothelium by immunohistochemistry (Ref. 50 and S. Hudak, unpublished observations). This may be due to CCL27 secretion by keratinocytes and subsequent binding of CCL27 to endothelial cell-associated glucosaminoglycans as has been described for CXCL8/IL-8 and CCL5/RANTES (51).
The CCR4 ligand CCL17/TARC protein is found on many venules in normal skin, but was drastically up-regulated on most (but not limited to) E-selectin+ venules in human psoriatic skin (16). These results contrast somewhat with Vestergaard et al. (17) who concluded that CCL17/TARC was not in normal skin, but was expressed by keratinocytes but not endothelial cells in AD patients. Because both CCL27 and CCL17/TARC protein are present on inflamed cutaneous endothelium, trigger rapid adhesion of CLA+ memory T cells, and stimulate CLA+ memory T cell migration, CCR4 and CCR10 may provide redundant mechanisms to allow CLA+/CCR4+/CCR10+ memory T cell entry into inflamed cutaneous sites. Importantly, CCR10 could not provide a redundant mechanism for all cells because it is only expressed by a subset of CLA+/CCR4+ T cells. Alternatively, CCR10 and CCR4 may act in a sequential manner to facilitate the specific microenvironmental homing of CLA+/CCR4+/CCR10+ memory T cells compared with the CLA+/CCR4+/CCR10- T cell population. The in vivo implications of specific spatial homing of these two populations are unclear at present.
CCR6+ memory T cells have also been implicated in
a variety of inflammatory skin conditions. CCR6 is expressed on some
CLA+ memory CD4 T cells, but is also found on the
4
7+
and a subset of the
CLA-/
4
7-
memory CD4 populations (52). CCR6 and its ligand
CCL20/MIP-3
are weakly expressed in normal skin, but are
up-regulated in psoriatic and AD lesions (19, 20), and
CCR6+ but not CCR6- memory
T cells roll and adhere to TNF-activated human dermal microvascular
endothelial cells (43). Figs. 4
B and 5, and
Table I
demonstrate that CCR6 is expressed on a subset of
CLA+/CCR10+ memory CD4 T
cells in normal peripheral blood. This is similar to the distribution
of CCR6 on the CLA+/CCR10-
and CLA- populations, suggesting a neutral
correlation between CCR10 and CCR6 expression in contrast to CCR10 and
CCR4 (positive association) or with CCR10 and CXCR3 (negative
association). Coexpression of CCR6 and CCR10 on some cells may provide
redundant mechanisms to facilitate their entry into inflamed cutaneous
sites or these chemokines may act sequentially to transport
CCR6+/CCR10+ memory CD4 T
cells into different microenvironments than would be accessible to
either CCR6+/CCR10- or
CCR6-/CCR10+CLA+
memory CD4 T cells.
CLA+/CCR10+ memory T cell
production of inflammatory cytokines following stimulation is
consistent with a significant number of cells being part of the EM
population. Importantly, basal mRNA levels (data not shown) and basal
CSC frequency measurement (i.e., in the absence of in vitro
stimulation) for inflammatory cytokines is consistent with
CCR10+ T cells in blood being memory, but not
acutely activated cells in normal donors. It will be interesting to
determine in various T cell-mediated skin disease patients whether
blood-derived CCR10+ cells have been acutely
activated and are actively secreting cytokines. However,
CCR10+ CD4 T cells can be induced to secrete
inflammatory cytokines such as the proinflammatory TNF and the
Th1-associated IFN-
. Production of TNF by activated skin-homing
cells within skin may provide a positive feedback loop to up-regulate
endothelial E-selectin expression, and thereby facilitate increased
leukocyte entry into the inflamed tissue. IFN-
production may
up-regulate MHC class II expression on keratinocytes, and with TNF
induce the expression of a wide variety of inflammatory chemokines such
as CXCL9/monokine induced by IFN-
, CXCL10/IP-10,
CXCL11/IFN-inducible T cell
-chemoattractant, CCL17/TARC, and
CCL20/MIP-3
. The combined actions of increased E-selectin,
inflammatory cytokines and chemokines, and increased class II
expression may establish a rich microenvironment to promote the
migration and activation of other leukocyte subsets in the lesion.
These cells under in vitro activation conditions produced little to no
IL-10 or Th2-associated IL-4 message (data not shown) or protein (Fig. 6
, C and D). It should be cautioned that in
disease situations such as the Th2-associated AD, there may be an
up-regulation of IL-4 production by CCR10+CD4 T
cells or a selective expansion of these cells that would change the
overall character of the cytokine production capabilities of the
CCR10+ memory CD4 T cell population.
In summary, a subset of blood-derived skin-homing memory CD4 and CD8 T cells express CCR10. CLA+/CCR10+ memory CD4 T cells express a variety of homing and CKRs that may enable them to scan both lymphoid and extralymphoid sites for the presence of non-self Ags. Once activated, these cells express a variety of inflammatory cytokines that would establish and/or maintain a rich inflammatory environment in the skin. The homing of these cells to skin and the subsequent cytokine production by them may have both beneficial and detrimental outcomes. Beneficial responses by these cells may protect the host from pathogenic microbes and skin-derived tumors. However, disregulated responses initiated by environmental factors or host genetic background may lead to inappropriate inflammation as seen in T cell-mediated skin diseases such as psoriasis and AD. Future studies devoted toward understanding CCR10s role in these diseases should be enlightening.
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Edward P. Bowman, DNAX Research, 901 California Avenue, Palo Alto, CA 94304-1104. E-mail address: ebowman{at}dnax.org ![]()
3 Abbreviations used in this paper: CLA, cutaneous lymphocyte-associated Ag; AD, atopic dermatitis; CKR, chemokine receptor; CSC, cytokine secreting cell; Ion, ionomycin; CCL, CC ligand; MIP, macrophage inflammatory protein; IP-10, IFN-
-inducible protein-10; h, human; EM, effector memory; CM, central memory. ![]()
Received for publication December 20, 2001. Accepted for publication May 29, 2002.
| References |
|---|
|
|
|---|
E
7 in the pathogenesis of psoriasis vulgaris. Lab. Invest. 81:335.[Medline]
/CCL20 and CC chemokine receptor 6 in psoriasis. J. Immunol. 164:6621.
/CCL20 by epidermal keratinocytes and its role in atopic dermatitis. Int. Immunol. 13:95.
in atopic eczema. Lancet 343:25.[Medline]
. J. Immunol. 162:186.This article has been cited by other articles:
![]() |
A. Miles, E. Liaskou, B. Eksteen, P. F. Lalor, and D. H. Adams CCL25 and CCL28 promote {alpha}4{beta}7-integrin-dependent adhesion of lymphocytes to MAdCAM-1 under shear flow Am J Physiol Gastrointest Liver Physiol, May 1, 2008; 294(5): G1257 - G1267. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-K. Shirakawa, D. Nagakubo, K. Hieshima, T. Nakayama, Z. Jin, and O. Yoshie 1,25-Dihydroxyvitamin D3 Induces CCR10 Expression in Terminally Differentiating Human B Cells J. Immunol., March 1, 2008; 180(5): 2786 - 2795. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Pivarcsi, A. Muller, A. Hippe, J. Rieker, A. van Lierop, M. Steinhoff, S. Seeliger, R. Kubitza, U. Pippirs, S. Meller, et al. Tumor immune escape by the loss of homeostatic chemokine expression PNAS, November 27, 2007; 104(48): 19055 - 19060. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Alvarez, J. L. Arkinson, J. Sun, R. Fattouh, T. Walker, and M. Jordana Th2 Differentiation in Distinct Lymph Nodes Influences the Site of Mucosal Th2 Immune-Inflammatory Responses J. Immunol., September 1, 2007; 179(5): 3287 - 3296. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Soler, T. R. Chapman, L. R. Poisson, L. Wang, J. Cote-Sierra, M. Ryan, A. McDonald, S. Badola, E. Fedyk, A. J. Coyle, et al. CCR8 Expression Identifies CD4 Memory T Cells Enriched for FOXP3+ Regulatory and Th2 Effector Lymphocytes J. Immunol., November 15, 2006; 177(10): 6940 - 6951. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Chen, S.-x. Lin, R. Agha-Majzoub, L. Overbergh, C. Mathieu, and L. S. Chan CCL27 is a critical factor for the development of atopic dermatitis in the keratin-14 IL-4 transgenic mouse model Int. Immunol., August 1, 2006; 18(8): 1233 - 1242. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. L. Humphreys, L. A. Baldridge, S. D. Billings, J. J. Campbell, and S. M. Spinola Trafficking Pathways and Characterization of CD4 and CD8 Cells Recruited to the Skin of Humans Experimentally Infected with Haemophilus ducreyi Infect. Immun., July 1, 2005; 73(7): 3896 - 3902. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Alvarez, G. Harder, R. Fattouh, J. Sun, S. Goncharova, M. R. Stampfli, A. J. Coyle, J. L. Bramson, and M. Jordana Cutaneous Antigen Priming via Gene Gun Leads to Skin-Selective Th2 Immune-Inflammatory Responses J. Immunol., February 1, 2005; 174(3): 1664 - 1674. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gunther, C. Bello-Fernandez, T. Kopp, J. Kund, N. Carballido-Perrig, S. Hinteregger, S. Fassl, C. Schwarzler, G. Lametschwandtner, G. Stingl, et al. CCL18 Is Expressed in Atopic Dermatitis and Mediates Skin Homing of Human Memory T Cells J. Immunol., February 1, 2005; 174(3): 1723 - 1728. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Hieshima, Y. Kawasaki, H. Hanamoto, T. Nakayama, D. Nagakubo, A. Kanamaru, and O. Yoshie CC Chemokine Ligands 25 and 28 Play Essential Roles in Intestinal Extravasation of IgA Antibody-Secreting Cells J. Immunol., September 15, 2004; 173(6): 3668 - 3675. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Masopust, V. Vezys, E. J. Usherwood, L. S. Cauley, S. Olson, A. L. Marzo, R. L. Ward, D. L. Woodland, and L. Lefrancois Activated Primary and Memory CD8 T Cells Migrate to Nonlymphoid Tissues Regardless of Site of Activation or Tissue of Origin J. Immunol., April 15, 2004; 172(8): 4875 - 4882. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. Lakkis and M. H. Sayegh Memory T Cells: A Hurdle to Immunologic Tolerance J. Am. Soc. Nephrol., September 1, 2003; 14(9): 2402 - 2410. [Full Text] [PDF] |
||||
![]() |
J.-Q. Gao, Y. Tsuda, K. Katayama, T. Nakayama, Y. Hatanaka, Y. Tani, H. Mizuguchi, T. Hayakawa, O. Yoshie, Y. Tsutsumi, et al. Antitumor Effect by Interleukin-11 Receptor {alpha}-Locus Chemokine/CCL27, Introduced into Tumor Cells through a Recombinant Adenovirus Vector Cancer Res., August 1, 2003; 63(15): 4420 - 4425. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Papadakis, C. Landers, J. Prehn, E. A. Kouroumalis, S. T. Moreno, J.-C. Gutierrez-Ramos, M. R. Hodge, and S. R. Targan CC Chemokine Receptor 9 Expression Defines a Subset of Peripheral Blood Lymphocytes with Mucosal T Cell Phenotype and Th1 or T-Regulatory 1 Cytokine Profile J. Immunol., July 1, 2003; 171(1): 159 - 165. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |